
Primary endocrine therapy (PET) has emerged as a valuable option for managing breast cancer in patients who cannot undergo curative surgery due to advanced age, comorbidities, or personal preference. This article delves into how PET is utilised, its benefits, limitations, and commonly asked questions about the approach.
What is Primary Endocrine Therapy?
Primary endocrine therapy involves using hormone-blocking medications to control the growth of hormone receptor-positive (HR+) breast cancer. It is particularly beneficial for postmenopausal patients whose tumours are fueled by oestrogen or progesterone.
Key medications include:
- Aromatase inhibitors (e.g., letrozole, anastrozole, exemestane): These drugs reduce oestrogen levels in the body.
- Selective oestrogen receptor modulators (SERMs) (e.g., tamoxifen): These block oestrogen from binding to its receptor.
Unlike adjuvant endocrine therapy, which is used after surgery, PET is the primary mode of treatment when surgery is not an option.
Why Use PET in Breast Cancer Management?
PET is a tailored approach for patients who are unsuitable for surgery due to various reasons, such as:
- Age and Frailty: Elderly patients with significant health issues may face higher surgical risks.
- Comorbidities: Conditions like severe cardiovascular or respiratory diseases make anaesthesia and surgery unsafe.
- Patient Choice: Some individuals may decline surgery and seek less invasive options.
- Tumour Characteristics: PET is most effective in hormone receptor-positive tumours, which depend on oestrogen or progesterone for growth.
Benefits of Primary Endocrine Therapy
- Non-invasive: PET avoids the physical and emotional stress of surgery.
- Effective Tumour Control: It can reduce tumour size and slow progression.
- Improved Quality of Life: Side effects are generally manageable, allowing many patients to maintain daily activities.
- Long-Term Treatment: PET can be used continuously for tumour suppression.
Limitations and Challenges
While PET offers several benefits, it is not without drawbacks:
- Limited Applicability: It is only effective for hormone receptor-positive tumours.
- Resistance Development: Over time, tumours may become resistant to endocrine therapy, reducing its efficacy.
- No Curative Intent: Unlike surgery, PET does not remove the tumour, making disease management more complex.
- Side Effects: Patients may experience hot flashes, joint pain, fatigue, or osteoporosis.
How Effective is PET?
Studies suggest that PET can be an effective option for controlling HR+ breast cancer in older or frail patients. Tumor response rates can reach 60–70%, with stable disease observed in an additional 20–30%. However, effectiveness depends on factors such as tumor biology, patient adherence to treatment, and overall health.
FAQs About Primary Endocrine Therapy
1. Who is a candidate for PET?
Patients with hormone receptor-positive breast cancer who are unable or unwilling to undergo surgery are ideal candidates for PET. Postmenopausal women derive the most benefit due to the lower baseline oestrogen levels.
2. How long does PET last?
Treatment is typically continuous, as stopping the therapy may lead to disease progression. Regular assessments ensure the treatment remains effective.
3. What are the alternatives if PET fails?
If PET is no longer effective, options include:
- Switching to another type of endocrine therapy.
- Combining endocrine therapy with targeted drugs like CDK4/6 inhibitors.
- Considering palliative treatments such as radiation or chemotherapy.
4. What side effects should I expect?
Common side effects include menopausal symptoms like hot flashes, mood changes, and decreased bone density. Doctors may prescribe supplements or other medications to manage these effects.
5. How is treatment response monitored?
Doctors monitor response using:
- Imaging tests (e.g., mammograms or ultrasounds).
- Tumour markers in blood tests.
- Physical examinations.
6. Can PET be combined with other therapies?
In some cases, PET is combined with targeted therapies to enhance effectiveness, especially in advanced-stage cancers.
Conclusion
Primary endocrine therapy provides a crucial lifeline for patients with hormone receptor-positive breast cancer who cannot undergo surgery. While not curative, it effectively controls tumour growth, alleviates symptoms, and improves quality of life. Regular follow-ups and a personalised approach are essential to optimise outcomes and address challenges as they arise.
For those navigating complex health scenarios, PET serves as a testament to the evolving and adaptable nature of cancer care.
Senthurun (Seni) Mylvaganam
Consultant Oncoplastic Breast Surgeon